CAMBRIDGE, United Kingdom, March 17,
2025 /PRNewswire/ -- IgniteData has announced a
collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) and
Cambridge University Hospitals NHS
Foundation Trust (CUH) to launch its Archer tool for clinical data
integration in an ongoing Phase 3 study sponsored by AstraZeneca.
This collaboration marks a significant milestone in IgniteData's
aim of transforming clinical trials through automation and digital
innovation.
IgniteData's Archer tool is a technology platform that upholds
the highest standards of data security and automates the data
transfer process between hospital Electronic Health Records (EHRs)
and sponsor Electronic Data Capture (EDCs), allowing researchers to
focus more of their time on clinical research and less time on data
entry. With its system-agnostic design, Archer integrates
effortlessly with leading EHRs and EDCs to map a multitude of study
variables and transfer several hundred data points per patient,
resulting in significant time savings while ensuring the highest
levels of data integrity and maintaining patient data privacy.
The collaboration between Cambridge
University Hospitals, AstraZeneca, and IgniteData began in
2021, with AstraZeneca playing a key role in developing the Archer
platform. After successful pilot studies at University College
London Hospitals (UCLH) and Memorial Sloan Kettering Cancer Center
(MSK), Archer is now being deployed in this pivotal study at
Cambridge. All participating
patients provided prior approval for the integration and use of
their clinical data in the study. This collaboration underscores
the commitment of both Cambridge
University Hospitals and AstraZeneca to advancing clinical
research through innovative technology. Dr. Wai Keong Wong, Clinical Director of Digital
Transformation at CUH, expressed enthusiasm for the project,
stating, "The integration of Archer into our EHR system represents
a significant leap forward in how we conduct clinical trials. The
automation of data capture not only enhances efficiency but also
ensures the highest standards of data integrity, which is crucial
for the success of our research and, ultimately, for patient
outcomes."
Richard Yeatman, COO of
IgniteData, added, "Our partnership with Cambridge University Hospitals and AstraZeneca is a
testament to the power of collaboration in advancing clinical
research. With Archer, we are laying the groundwork for a new era
of digital innovation in clinical trials, one where data is
transferred seamlessly, securely, and efficiently."
Looking Ahead
The data and insights gained from this
live integration will inform future deployments of Archer across
other NHS and European hospitals. This marks just the beginning of
a broader initiative to scale this technology globally with
approved sponsors, transforming the way clinical trials are
conducted and accelerating the delivery of life-saving treatments
to patients.
For more information about Archer and its role in modern
clinical trials, visit IgniteData's website.
About IgniteData
IgniteData is the company shaping the
future of clinical trials. Through its innovative digihealth
platform, Archer, it is enhancing interoperability between
Electronic Health Records (EHR) and key research applications such
as Electronic Data Capture (EDC).
IgniteData is transforming the future of clinical trials through
its cloud-based Virtual Research Assistant, Archer. A
system-agnostic solution, Archer brings modern interoperability
between EHR and key research systems, such as EDC, to provide
seamless, secure transfer of clinically- validated data for
clinical trials.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ignitedata-launches-cutting-edge-data-integration-platform-for-clinical-trials-at-cambridge-university-hospitals-302403035.html
SOURCE IgniteData
